Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The human rotavirus vaccine, live attenuated, is a type of vaccine designed to protect against rotavirus infections, which are a primary cause of severe gastroenteritis, vomiting, and diarrhea in infants and young children. This vaccine contains weakened (attenuated) live rotavirus strains that, upon oral administration, replicate in the small intestine. This replication stimulates the body's immune system to produce antibodies and cellular immunity, thereby inducing active immunity against rotavirus gastroenteritis without causing the full-blown disease. GlaxoSmithKline is a developer of such a vaccine, with one specific product identified as GSK2202083A.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human rotavirus vaccine, live attenuated.